Navigation Links
MEDRAD(R) Revenues Grow 10 Percent in 2007
Date:3/4/2008

Highlights Include Patient Care Innovations and New Facilities

INDIANOLA, Pa., March 4 /PRNewswire/ -- MEDRAD, INC.'s sales revenues grew to $525 million in 2007, an increase of 10 percent over the previous year. A worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body, MEDRAD has achieved a double-digit annual revenue growth for over 10 years.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )

2007 business highlights include product innovations designed to improve patient care and the opening of new Global Center and syringe manufacturing facilities in the Western Pennsylvania region.

"We continue to focus on the goal of improving patient care through better diagnostic and treatment technologies," said John P. Friel, president and CEO. "MEDRAD's growth is grounded in our commitment to genuinely understand the needs of our customers and improve patient outcomes with more innovative, cost-efficient products."

Computed Tomography (CT) product innovations were led by new extravasation detector technology that, when properly employed, directly senses extravasation pooling of contrast agent under the skin during a CT scanning procedure. If left undetected, extravasation can cause significant patient discomfort. Personalized Patient Protocol Technology (P3T) was also launched in CT, making it possible to further customize an injection based on patient- specific parameters. The benefit is even more consistent, high-quality diagnostic cardiac images, and greater safety and efficiency in terms of reducing the volume of contrast agent needed for each procedure.

The company's Magnetic Resonance (MR) endorectal coil was upgraded to be compatible with the new versions of scanners recently launched by the major scanner manufacturers. The coil continues to conform to the size and shape of the prostate to provide clearer pictures needed to diagnose and stage cancer and plan targeted treatment. MEDRAD also partnered with the National Prostate Cancer Coalition (NPCC) to provide information about prostate MR imaging to thousands of men who participate in its free mobile screening program.

MEDRAD opened a new 125,000-square-foot Global Center office facility in Warrendale, Pennsylvania, which now houses 260 sales, service, customer support and general administrative employees. A new 120,000-square-foot disposables manufacturing facility was also built in Saxonburg, Pennsylvania, and went from ground breaking to start up in just 10 months. At the heart of the facility is an extensive clean room environment in which workers manufacture disposable components used to inject contrast dyes during medical imaging procedures.

MEDRAD's Heilman Center electro-mechanical manufacturing plant, located in O'Hara Township, Pennsylvania was selected as a 2007 IndustryWeek magazine "Best Plant" award winner. This award is issued annually to plants that are on the leading edge of efforts to increase competitiveness, enhance customer satisfaction and create stimulating and rewarding work environments.

MEDRAD's employee base grew almost five percent in 2007, with a net of 70 full-time employees added. The company employed over 1,700 at year-end, of which 1,200 are located in the Pittsburgh region. The company recently announced it has signed a merger agreement with Possis Medical, Inc., a Minneapolis, Minnesota-based company with approximately 280 employees, pursuant to the terms of which the company launched a public tender offer to acquire all of the shares of Possis for a price of $19.50 per share. Possis is a leading provider of mechanical thrombectomy devices used to treat narrowed or blocked arteries and veins. If the tender offer receives the required regulatory approvals, the required number of shareholders tender their shares, and the other conditions of the deal are satisfied, the merger will be consummated, and Possis will become the cornerstone of MEDRAD's cardiovascular strategy.

MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2007 revenues were $525 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. More company information is available at http://www.medrad.com.

Bayer AG is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The Pharmaceuticals division comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology, Primary Care, and Oncology. The company's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well being and quality of life by diagnosing, preventing and treating diseases.

Cautionary statement regarding forward-looking statements. Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC. undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.


'/>"/>
SOURCE MEDRAD, INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
2. Kendle Delivers Strong Growth in Revenues, New Business Authorizations and Operating Margin for Full-Year 2007; Announces Guidance for 2008
3. Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent
4. Sodium Content Foods and Beverages Gain Revenues as Americans are Embracing Low- and No-Sodium Campaigns
5. Otter Tail Corporation Reports Record Revenues and Net Income From Continuing Operations for 2007; Earnings Per Share of $1.78; Board Approves Dividend Increase
6. Natural Nutrition Operating Subsidiary Reports Record 29% Increase in Revenues for 2007 of $17,460,000
7. Medical Services International Predicts Revenues for the Second Half of the Year
8. Cord Blood America Revenues Up 121 Percent in First Nine Months of 2007
9. Volcano Reports Record Third Quarter Revenues
10. Profarmas Gross Revenues Reached R$ 698.2 Million in the 3rd Quarter 2007, a 31.9% Growth Over the Same Period Last Year and Net Income Rose by 94.9%, Respectively
11. Nexia Closes Acquisition of Green Endeavors; Landis Salons On Track to Generate Revenues of $2.2 Million in 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... SC (PRWEB) , ... February 28, 2017 , ... ... is the premiere organization in North America for the scientific development, healthcare training ... its 2017 Annual Meeting & Scientific Session on September 16-17 in Greenville, SC ...
(Date:2/28/2017)... Salt Lake City, Utah (PRWEB) , ... February 28, 2017 , ... ... Heart Month is a time for everyone to reaffirm their commitment to improving cardiovascular ... leading cause of death for men and women. Every year, one in four deaths ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... from 4:30-5:30 p.m. at the 11th Annual RISE Nashville Summit. RISE Nashville is ... performance analytics, and engagement strategies. , The discussion will include best practices for ...
(Date:2/27/2017)... Austin, TX (PRWEB) , ... February 27, 2017 , ... ... of a large medical group. But his impoverished upbringing and life experiences could have ... to Become a Physician: Insightful and Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. ...
(Date:2/27/2017)... ... ... not your typical author. She went from working as a movie extra on Bill Murray’s ... she isn’t swimming as a performing mermaid. , Her book isn’t typical either. In Carothers’ ... comedic look at the dysfunctions of God’s family, before Lucifer was sent to hell. ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... ... Markets has announced the addition of the "Ovarian Cancer Drugs Price ... The latest research Ovarian Cancer Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Ovarian Cancer ...
(Date:2/28/2017)... , Feb. 28, 2017  Rigel Pharmaceuticals, Inc. ... it will report its fourth quarter and year ... March 7, 2017.  Rigel senior management will follow ... webcast at 5:00pm Eastern Time (2:00pm Pacific Time) ... can access the live conference call by dialing ...
(Date:2/28/2017)... , February 27, 2017 ... BioMedical assets for potential ... LOI contemplates capital infusion into Amarantus to assist ... Amarantus names four new appointees to its Board of Directors and ... SeD Biomedical Inc. (SeD Biomedical) , a ...
Breaking Medicine Technology: